It is relieving that others have spotted this as well.
This is a publicly traded company and shareholders need to be told what the status is with to those major plans. WE own the company!
Remember when Epitan acquired some licensed dermatology products years ago? That didn't work out at all.
Yes, that was a different mgmt team. My point is if they would have just gotten this to the market by now (which if you review the market plans back in 2006 was the original timeline) and wouldn't just have this orhpan indications with other larger-market indications so far off from commercialization, they wouldn't be in this spot.
I am not excited about the possibility of some kind of small acquisition if that is what they are considering.
What I was excited about was a Phase III US trial in 2011, PLE being delivered by now(chance for off-label sales), cuv9900 being updated in Q1. To not even list that or the US Phase III as one of their planned major objectives in 2011 is ridiculous.
The only good news I've seen from the letter is the European PHase III confirmation study patients will have finished their trial in May.
But to brush off the other things as you mentioned is really unsettling for me.
It is relieving that others have spotted this as well. This is a...
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.28 |
Change
-0.250(1.85%) |
Mkt cap ! $664.8M | |||
| Open | High | Low | Value | Volume |
| $13.55 | $13.62 | $13.25 | $1.157M | 86.45K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 227 | $13.28 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.42 | 228 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| CUV (ASX) Chart |